Artículo de Revisión 82.- Di Martini A, Day N, Dew MA, Javed L, 30 Fitzgerald MG, Jain A, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liv Transpl 2006; 12: 813-20. 83.- Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-800. 84.- Singal AK, Shah VH. Alcoholic hepatitis: prognostic models and treatment. Gastroenterol Clin N Am 2011; 40: 611-39. 85.- Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, et al. Intestinal decontamination improves Enfe rmedad hep ática po r alcohol - R. Lazarte C. et al. liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009; 29: 992-9. 86.- Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-5. 87.- Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, Yeoh GC, et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010; 52: 291-302. 88.- Gao B. Hepatoprotective and antiinflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol 2012; 27 (Suppl 2): 89-93. 89.- Israel Y, Rivera-Meza M, Karahanian E, Quintanilla ME, Tampier L, Morales P, et al. Gene specific modifications unravel ethanol and acetaldehyde actions. Front Behav Neurosci 2013: 7; 80. 90.- Tampier L, Quintanilla ME, Israel Y. Tolerance to disulfiram induced by chronic alcohol intake in the rat. Alcohol Clin Exp Res 2008; 32: 937-41. 91.- Karahanian E, Quintanilla ME, Fernández K, Israel Y. Fenofibrate-a lipid-lowering drug-reduces voluntary alcohol drinking in rats. Alcohol 2014; 48: 665-70. Gastroenterol. latinoam 2016; Vol 27, Nº 1: 18-30
gastro-1-2016
To see the actual publication please follow the link above